Drugs that specifically inhibit BCR signaling elements are currently being tested in clinical trials. The promising results obtained so far suggest that in the near future we may have novel ...

BCR–ABL1 was found to be involved in stemness regulation and ERK1/2 to have a key role in the signaling pathway. TKIs unexpectedly promoted stemness marker expression in Ph+ iPSC clones.